These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 26303956)

  • 1. Autoimmunity. Necrosis of IL-1β-containing monocytes may drive NOMID.
    Barranco C
    Nat Rev Rheumatol; 2015 Oct; 11(10):564. PubMed ID: 26303956
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of Interleukin-1β-Producing Monocytes That Are Susceptible to Pyronecrotic Cell Death in Patients With Neonatal-Onset Multisystem Inflammatory Disease.
    Edwan JH; Goldbach-Mansky R; Colbert RA
    Arthritis Rheumatol; 2015 Dec; 67(12):3286-97. PubMed ID: 26245468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging role of interleukin-1β in autoinflammatory diseases.
    Lachmann HJ; Quartier P; So A; Hawkins PN
    Arthritis Rheum; 2011 Feb; 63(2):314-24. PubMed ID: 20967858
    [No Abstract]   [Full Text] [Related]  

  • 4. Proton pump inhibitors protect mice from acute systemic inflammation and induce long-term cross-tolerance.
    Balza E; Piccioli P; Carta S; Lavieri R; Gattorno M; Semino C; Castellani P; Rubartelli A
    Cell Death Dis; 2016 Jul; 7(7):e2304. PubMed ID: 27441656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful management of cryopyrin-associated periodic syndrome with canakinumab in infancy.
    Kanariou M; Tantou S; Varela I; Raptaki M; Petropoulou C; Nikas I; Valari M
    Pediatrics; 2014 Nov; 134(5):e1468-73. PubMed ID: 25349319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
    Church LD; McDermott MF
    Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anakinra for cryopyrin-associated periodic syndrome.
    Koné-Paut I; Galeotti C
    Expert Rev Clin Immunol; 2014 Jan; 10(1):7-18. PubMed ID: 24308832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.
    Koné-Paut I; Galeotti C
    Expert Rev Clin Immunol; 2015; 11(10):1083-92. PubMed ID: 26312542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryopyrin-associated periodic syndromes: background and therapeutics.
    Kubota T; Koike R
    Mod Rheumatol; 2010 Jun; 20(3):213-21. PubMed ID: 20140476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.
    Anton J; Calvo I; Fernández-Martin J; Gamir ML; Merino R; Jimenez-Treviño S; Sevilla B; Cabades F; Bou R; Arostegui JI
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S67-71. PubMed ID: 26243511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Canakinumab: a promising treatment in rheumatology].
    Fabreguet I; So A
    Rev Med Suisse; 2012 Jan; 8(323):57-60. PubMed ID: 22303742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed reactivation of chronic infantile neurologic, cutaneous, articular syndrome (CINCA) in a patient with somatic mosaicism of CIAS1/NLRP3 gene after withdrawal of anti-IL-1 beta therapy.
    Paloni G; Pastore S; Tommasini A; Lepore L; Taddio A
    Clin Exp Rheumatol; 2015; 33(5):766. PubMed ID: 26316056
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical and Molecular Phenotypes of Low-Penetrance Variants of NLRP3: Diagnostic and Therapeutic Challenges.
    Kuemmerle-Deschner JB; Verma D; Endres T; Broderick L; de Jesus AA; Hofer F; Blank N; Krause K; Rietschel C; Horneff G; Aksentijevich I; Lohse P; Goldbach-Mansky R; Hoffman HM; Benseler SM
    Arthritis Rheumatol; 2017 Nov; 69(11):2233-2240. PubMed ID: 28692792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-1β in innate inflammation, autophagy and immunity.
    Joosten LA; Netea MG; Dinarello CA
    Semin Immunol; 2013 Dec; 25(6):416-24. PubMed ID: 24275601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful Treatment of CINCA/NOMID Syndrome with Interleukin-1 Blockade.
    Macejová Z; Vargová V; Matejka M; Szekanecz Z
    Isr Med Assoc J; 2015 Jun; 17(6):389-91. PubMed ID: 26234003
    [No Abstract]   [Full Text] [Related]  

  • 16. Longterm followup of quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab, an anti-interleukin 1β monoclonal antibody.
    Marsaud C; Marie I; Koné-Paut I
    J Rheumatol; 2014 Aug; 41(8):1721-2. PubMed ID: 25086140
    [No Abstract]   [Full Text] [Related]  

  • 17. The inflammasome and IL-1β: implications for the treatment of inflammatory diseases.
    Satoh T; Otsuka A; Contassot E; French LE
    Immunotherapy; 2015; 7(3):243-54. PubMed ID: 25804477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canakinumab for treatment of cryopyrin-associated periodic syndrome.
    Feist E; Burmester GR
    Expert Opin Biol Ther; 2010 Nov; 10(11):1631-6. PubMed ID: 20955115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. POPsicle for Fever! Cooling Down the Inflammasome.
    Shimada K; Crother TR; Arditi M
    Immunity; 2015 Aug; 43(2):213-5. PubMed ID: 26287676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased NLRP3-dependent interleukin 1β secretion in patients with familial Mediterranean fever: correlation with MEFV genotype.
    Omenetti A; Carta S; Delfino L; Martini A; Gattorno M; Rubartelli A
    Ann Rheum Dis; 2014 Feb; 73(2):462-9. PubMed ID: 23505242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.